Subject: Improving Screening | One Dose HPV Vaccine | Immunotherapy, Cancer Information Highlights, 03/31/2021
From: National Cancer Institute <[email-masked]>
To: [email-masked]
Date: Wed, 31 Mar 2021 17:54:30 +0000

Having trouble viewing this email? View it as a Web page.

Cancer Information Highlights

From the National Cancer Institute

Updating you about cancer causes, prevention, screening, treatment, coping, and more

New from NCI

Text Messages Improved Colon and Rectal Cancer Screening in Underserved Community

Results from a new study show that combining text messages with free at-home test kits helped boost colorectal cancer screening among people who have traditionally low screening rates.

Meet the Epidemiologist Reaching across Borders to Save Lives

A team led by Dr. Aimée Kreimer has found that one dose of the human papillomavirus (HPV) vaccine provides long-term protection against cervical cancer, which kills 300,000 people per year worldwide. She is working with researchers in Costa Rica to confirm the team’s findings. Learn more about efforts to prevent cervical cancer.

Engineered Immune Cells Prevented Cancer from Spreading in Mice

In an NCI study, injecting mice with immune cells that were changed in the lab shrank tumors and prevented cancer from spreading to other parts of the body. The immunotherapy approach shows promise as a treatment for cancer in humans that has spread.

Targeted Therapy Slows Growth of Kidney Cancer

Results from a new study show that cabozantinib (Cabometyx) is the most effective treatment option to date for some people with papillary renal cell carcinoma (PRCC), a type of kidney cancer.

Hormone Therapy for Breast Cancer

We’ve updated our page describing hormone therapy and its role in treating breast cancer. Learn about the types of hormone therapy, how they are used, and possible side effects.

PDQ Updates

Cannabis and Cannabinoids

We’ve updated our PDQ summary with information about studies that have been done to find out how cannabis interacts with conventional therapy.

FDA Approvals

Melphalan Flufenamide Hydrochloride

We’ve added a new drug summary for melphalan flufenamide hydrochloride (Pepaxto), which the Food and Drug Administration recently approved to be used in combination with dexamethasone to treat multiple myeloma that has relapsed or stopped responding to certain types of treatments.

Also of Interest

Sleep Disorders

Sleep is an important part of physical and mental health. Explore this page to learn why getting enough sleep is important, why sleep disorders are common in people with cancer, and what treatment options are available.

NCI COVID-19 Research Initiatives

NCI is adding to the global effort to address COVID-19 by rallying its scientific experts and cutting-edge resources to conduct research on the SARS-CoV-2 virus. Learn about the different research efforts.

Contact Us for Help

Information specialists at NCI’s Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.

Stay Connected with the National Cancer Institute

Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237)

SUBSCRIBER SERVICES:
Manage Subscriptions  |  Help

This email was sent to [email-masked] using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892